To Reduce Dementia Risk, Treat High Blood Pressure
Treating high blood pressure for as little as four years can cut the risk of dementia by 15 percent, according to clinical a trial results published on Monday in Nature Medicine. In the investigation, intensive blood pressure reduction also lowered the risk of mild cognitive impairment, an early stage of memory loss in people who can still live independently, by 16 percent.
Although research has long linked hypertension and dementia, the new study provides the strongest evidence yet that taking medications for the former actually reduces someone's risk of developing the latter.
'Our study shows that dementia is preventable,' says Jiang He, a physician who studies epidemiology, internal medicine and neurology at the University of Texas Southwestern Medical Center.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
The researchers studied nearly 34,000 people with high blood pressure in rural Chinese villages. The team randomly assigned half of the villages to an intensive hypertension reduction program, and people in the other villages received their normal care. After four years, 4.6 percent of those who underwent intensive blood pressure control—the goal of which was to lower their blood pressure to less than 130/80 millimeters of mercury (mm HG)—were diagnosed with dementia compared with 5.4 percent in the group that received standard care. Because doctors treated people for only four years, it's not known if controlling blood pressure for a longer period of time would further reduce the dementia risk.
Those results provide 'strong evidence' to support using antihypertensive medications to prevent dementia in people with high blood pressure, He said.
Beth Abramson, who studies cardiac disease prevention and women's health at the University of Toronto, calls the results encouraging. Many people ignore their hypertension or fail to take medications as directed, even though the condition can cause heart attacks and strokes, says Abramson, who is co-chair of the American College of Cardiology Hypertension Workgroup and was not involved in the new study.
In the U.S., 48 percent of adults have hypertension, defined as a blood pressure that is consistently at or above 130/80 mm HG.
The hope of preventing dementia may motivate some people to take their blood pressure more seriously, says Mitchell S. V. Elkind, chief clinical science officer at the American Heart Association, who also wasn't involved in the new study. Surveys show dementia is one of the diseases that Americans fear most.
According to the World Health Organization, 57 million people worldwide had dementia in 2021. This number is expected to nearly double every 20 years, reaching 82 million in 2030 and 152 million in 2050, according to the nonprofit organization Alzheimer's Disease International.
The new findings resemble those from separate clinical trial research published in January in Neurology. That study treated people with hypertension for 3.3 years and followed them for a median of seven years. The investigation focused on lowering systolic blood pressure, the first number in a blood pressure reading, in older adults. Of the 4,200 people in the study who underwent cognitive assessment, the group that who decreased systolic blood pressure to less than 120 mm HG had a reduced risk of mild cognitive impairment or probable dementia; these participants' risk was lowered by 11 percent compared with people who decreased their systolic blood pressure to below 140 mm HG. The study didn't find any difference in the risk of probable dementia alone—possibly because it was smaller than the new study in China, because dementia can take many years to develop or because the trial was stopped early thanks to its overwhelmingly positive results in preventing cardiovascular events.
Scientists don't know exactly how hypertension might contribute to dementia, says David Reboussin, a professor of biostatistics and data science at the Wake Forest University School of Medicine and first author of the January Neurology study. But, he adds, 'if there is anything going on with small vessels and their ability to get oxygen to the brain tissue, then brain tissue will suffer. It will atrophy and die.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
27 minutes ago
- Time Magazine
Trump's First Surgeon General: RFK Jr. Purging the CDC Advisory Committee Will Put Lives at Risk
When Secretary Robert F. Kennedy Jr. began his tenure as Health and Human Services Secretary, he pledged, 'We won't take away anyone's vaccines.' However, recent policy changes under his leadership—coupled with the unprecedented dismissal of all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP) on June 9—have proven that statement false, raising grave concerns for our nation's COVID-19 response and broader vaccine policies. These shifts not only jeopardize public health but also threaten to erode trust in our health institutions at a critical time. In May 2025, the Food and Drug Administration (FDA) introduced a new COVID-19 vaccine framework, limiting access to updated vaccines for Americans aged 65 and older or those with specific risk factors. Furthermore, Secretary Kennedy announced that the Centers for Disease Control and Prevention (CDC) would no longer recommend COVID-19 vaccines for 'healthy' children or pregnant women—bypassing the standard ACIP review process. Compounding these changes, the abrupt removal of ACIP's entire panel of independent experts, who have guided evidence-based vaccine policy for decades, risks destabilizing a cornerstone of public health. These actions collectively restrict access to a vital tool for saving lives and undermine confidence in our health systems. During my tenure as Surgeon General under the first Trump administration, we faced significant public health challenges, from addressing the opioid epidemic by increasing access to Naloxone to launching Operation Warp Speed for the COVID-19 vaccine development effort. The vaccines developed under Trump's first term have proven to be one of our most effective defenses against COVID-19; yet, the current administration's new policies limit their availability, potentially leaving millions vulnerable. The dismissal of ACIP's experts—without a clear plan for replacing them with qualified scientists—further jeopardizes trust in the institutions tasked with protecting Americans. The major flaw in the new vaccine framework is its narrow assessment of risk. Although the immediate dangers of COVID-19 have lessened, it remains a leading cause of death and hospitalization, claiming nearly 50,000 lives in the U.S. in 2024—more than breast cancer or car accidents. The fact is, 75% of Americans have risk factors, such as obesity or diabetes, that increase their vulnerability to severe COVID outcomes. However, the burden is now placed on individuals to self-identify as high risk, creating confusion and inconsistency in access. Unlike other countries with centralized systems for identifying at-risk individuals, the U.S. expects patients—many of whom lack easy access to healthcare—to navigate eligibility alone. Risk assessment should also consider individual circumstances beyond underlying health conditions. A 58-year-old bus driver or healthcare worker faces significantly greater exposure than someone working remotely. By limiting vaccines to specific groups based solely on preexisting health status, the policy overlooks these critical contextual differences. Secretary Kennedy's team argues that there is insufficient evidence to support updated COVID-19 vaccines for healthy Americans under 65, but this claim is flatly unfounded. Years of real-world data demonstrate that vaccines save lives and reduce hospitalizations across all age groups. During the 2023 to 2024 fall and winter season, 95% of those hospitalized for COVID had not received an updated vaccine. While the administration cites other countries' more restrictive vaccine policies, such comparisons ignore the unique health landscape in the U.S., which includes higher obesity rates, worse maternal health outcomes, and uneven healthcare access. The policy also neglects the issue of Long COVID, which affects millions with debilitating symptoms lasting months or years. Though older adults are at higher risk for severe acute infections, Long COVID disproportionately impacts adults aged 35 to 49—and children are also affected. Vaccination reduces the risk of developing Long COVID, an essential reason many healthy individuals choose to stay up-to-date with their vaccines. Particularly concerning is the decision to end COVID vaccine recommendations for 'healthy' pregnant women, which contradicts the FDA's own guidance. Pregnant women face heightened risks of severe COVID outcomes, including death, pre-eclampsia, and miscarriage. Vaccination during pregnancy is crucial—not just for maternal health but also for protecting infants under six months, who cannot be vaccinated and rely on maternal antibodies for protection. Decades of research confirm that vaccines, including COVID vaccines, safely transfer antibodies to newborns, lowering their risk of severe illness. The dismissal of ACIP's members amplifies these concerns. ACIP has been a trusted, science-driven body that ensures vaccines are safe and effective, saving countless lives through its transparent recommendations. Its members, rigorously vetted for expertise and conflicts of interest, provide independent guidance critical to public health. Removing them without clear evidence of misconduct risks replacing qualified scientists with less experienced voices. This move fuels vaccine hesitancy and skepticism about public health decisions, particularly when paired with the bypassing of ACIP's review process for the new COVID vaccine policies. These changes create uncertainty about who can access vaccines. Without clear CDC recommendations, insurance companies may impose their own coverage criteria, potentially increasing costs for a vaccine that was previously free for most Americans. Healthcare providers, lacking federal guidance and ACIP's expertise, may struggle to advise patients, leading to a confusing and inequitable system that limits choice—hardly the 'medical freedom' Secretary Kennedy claims to champion. Ultimately, these actions threaten to erode trust in public health. FDA officials argue the new framework enhances transparency, yet bypassing ACIP's review and dismissing its members undermines that aim. Extensive data demonstrate that updated vaccines lower hospitalization and death rates, yet this evidence was sidelined. Such actions breed skepticism, making it harder to unite Americans around shared health goals. The stakes are high, but a better path is possible. Restoring trust requires transparent, evidence-based policymaking that prioritizes access to life-saving tools. I urge Secretary Kennedy and the administration to reconsider this framework, reinstate ACIP's role in vaccine policy, and ensure any new appointees are qualified, independent experts. If concerns about ACIP exist, they should be addressed through reform, not dissolution. Healthcare providers and community leaders must also educate patients about vaccination benefits, particularly for vulnerable groups like pregnant women and those with high exposure. Individuals can take action by staying informed, discussing vaccination with their doctors, and advocating for clear, equitable access to vaccines. By working together—government, providers, and citizens—we can protect lives, reduce the burden of Long COVID, and rebuild confidence in our public health system. We must seize this opportunity to unite around science and ensure a healthier, safer, and prosperous future for all Americans.
New York Post
28 minutes ago
- New York Post
Widely-used drug can seriously increase women's odds of living to age 90
Time to re-up that AARP subscription. A popular prescription drug already in millions of medicine cabinets could be the key to unlocking a longer life for women. New research published in the Journal of Gerontology: Medical Sciences found that those taking this widely-used diabetes drug had a great shot at making it to the big 9-0. JackF – No, it's not Ozempic — it's called metformin, and almost 20 million Americans are estimated to be taking it to help manage their Type 2 diabetes. Like other diabetes drugs, this decades-old, dirt-cheap medication works by decreasing the amount of glucose the body absorbs from food and improves its response to insulin. Also used to treat Polycystic Ovary Syndrome (PCOS), metformin has often been hailed as a 'wonder drug' due to its other health benefits, including improving fertility in women, aiding in weight management and even reducing the risks of heart disease and certain cancers. This new study set its sights on promising research indicating it may also have anti-aging effects. Researchers analyzed the data of 438 postmenopausal women — half of whom were on metformin, the other half of whom took another diabetes drug called sulfonylurea. Like other diabetes drugs, metformin works by decreasing the amount of glucose the body absorbs from food and improves its response to insulin. Halfpoint – They found that those in the metformin group had a 30% higher chance of making it to 90 when compared to the sulfonylurea group. The study has a few limitations, the most notable of which is that it had no control group — meaning none of the participants weren't on diabetes medication — as well as a relatively small sample size. However, one of its strengths was a follow-up period of 14-15 years, which is much longer than the average randomized controlled trial. All told, the new study adds to an increasing body of research on the geroscience hypothesis, which posits that 'biological aging is malleable and that slowing biological aging may delay or prevent the onset of multiple age-related diseases and disability,' the researchers wrote. The new study backs up previous research published last year which showed that metformin can slow aging and also prevent disease in healthy older adults. 'I don't know if metformin increases lifespan in people, but the evidence that exists suggests that it very well might,' Steven Austad, a senior scientific adviser at the American Federation for Aging Research who studies the biology of agin, told NPR. While scientists figure out how to biohack our systems, this little pill may just propel you into your golden years.
Yahoo
38 minutes ago
- Yahoo
A 41-year-old longevity doctor says his 'biological age' is 24. He takes 3 supplements daily.
Dr. Mohammed Enayat, the founder of a longevity clinic, says he's reversed his "biological age" by 17 years. He told Business Insider that supplements are a part of his longevity routine. He takes B complex and folate, magnesium, and omega-3 fatty acids daily. Dr. Mohammed Enayat has access to all sorts of experimental antiaging treatments at his clinic, but a core part of his longevity routine is pretty cheap and accessible: supplements. Enayat told Business Insider that his most recent "biological age" tests, taken 18 months ago, said he was 24, or 17 years younger than his chronological age of 41. There's no consensus on how to define or measure biological age, but Enayat used GlycanAge and TruAge PACE, which measure inflammation and epigenetics, respectively. The primary care doctor, who's also the founder of London's Hum2n longevity clinic, has been closely tracking his health for the past seven years, using wearable tech, including an Oura ring and a Whoop strap, plus regular blood, urine, and microbiome tests. Enayat changes his longevity routine, including the supplements he takes, depending on the results. But he has taken what he sees as his "core" supplements, B complex and folate, magnesium, and omega-3 fatty acids, daily in cycles over the past several years, he said. "While I believe these supplements have supported my biological age reversal, I credit them as one component in a much broader framework," Enayat added. In general, dietitians recommend that people prioritize getting their nutrients from food and supplementing if they have deficiencies or are unable to eat certain nutritious foods. Enayat takes a vitamin B complex and folate supplement. "I have a methylation gene defect, which means that my homocysteine, one of the markers, rises high, which is very pro-inflammatory. So to bring that down, I have to be on a good B complex and a folate supplement," he said. Having high levels of homocysteine can increase the risk of blood clots, heart attack, and stroke. But you can lower your levels through supplementation and eating foods that contain B vitamins, including fish, poultry, legumes, seeds, eggs, dairy products, and leafy greens. More broadly, studies have linked B vitamins to better mood and the prevention of dementia, but more research is needed. "Even without a methylation-related gene defect, I would still consider taking a methylated B complex, particularly during periods of high stress, poor sleep, or intensive training, as these increase the demand for B vitamins," Enayat said. Magnesium is found in legumes, dark leafy greens, nuts, seeds, and whole grains. It plays a key role in many biological processes, including building strong bones, regulating blood sugar and blood pressure, and muscle function. Enayat's magnesium is below the recommended level, he said, because he doesn't get enough from his diet. This is relatively uncommon — about 2% of Americans have low magnesium levels. For this, he takes a form of magnesium called bisglycinate because it's easier for the body to absorb. "It works really well to bring my levels up," he said. When he takes magnesium, he finds that his muscles ache less and he falls asleep more easily. Omega-3 fatty acids, found in foods including oily fish, walnuts, and chia seeds, have been linked to better heart health, lower inflammation, and lower blood pressure. Enayat has naturally low levels of omega-3 fatty acids, so he takes a daily supplement. There's strong evidence to suggest that eating fatty fish weekly is protective against cardiovascular disease, but it's unclear whether taking it in supplement form provides the same protection. There is, however, some evidence to suggest that taking omega-3 supplements may have antiaging effects. A study on 777 participants with an average age of 75, published in the journal Nature Aging earlier this year, found that those who consumed a gram of omega-3s every day had lower "biological ages" than those who didn't. Read the original article on Business Insider
